Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout SemaglutideGLPOne.com.

SELECT Trial Results — Cardiovascular Outcomes

SELECT Trial Results

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

Clinical referencePubMed-linkedUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Reviewed by Julliana Edwards (Editor) · Last updated 2026-05-08

Overview

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

PubMed citations

PMID 37952131

Related clinical pages

STEP trial results
SELECT trial results
FLOW trial results
Mechanism of action
Dosing & pharmacology
Contraindications
Side effects